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Abstract
This paper presents a novel health monitoring system for Parkinson’s disease (pd) patients called help (Home-based 
Empowered Living for Parkinson’s disease patients). The help system has been specifically designed and implemented 
as a health monitoring system in order to optimize treatment and improve quality of life of people with Parkinson’s. 
This is a challenging goal due to the difficulty in establishing a closed-loop system that is able to detect the outcomes 
of treatment and react accordingly. In a similar way to diabetes treatment where the plasma glucose level can be 
measured and can be used to regulate drug doses, the help system’s approach aims to estimate pd symptoms and to 
adjust the dose of medication in order to reduce symptoms. The proposed health monitoring system is composed of 
several components: a body sensor & actuator network managed by a smartphone, a remote monitoring platform for 
doctors and clinical professionals as well as a telecommunication and service infrastructure. The real advantage de-
rives from having constant medical control without dramatically modifying daily life. The help system is going to be 
evaluated in several cities during the first part of 2012 under daily living conditions with pd patients.
Keywords: Parkinson’s Disease, Body Sensor and Actuator Network, Health Monitoring System, Ambient Assisted 
Living
Resumen
En este trabajo se presenta un nuevo sistema de vigilancia de la salud para pacientes con la enfermedad de Parkin-
son (ep), pacientes llamados help (Fortaleciendo la vida en el hogar de pacientes con la enfermedad Parkinson). El 
sistema de ayuda ha sido específicamente diseñado e implementado como un sistema de vigilancia de la salud con 
el fin de optimizar el tratamiento y mejorar la calidad de vida de las personas con Parkinson. Este es un objetivo difícil 
debido a la dificultad del establecimiento de un sistema de circuito cerrado que es capaz de detectar los resultados 
del tratamiento y reaccionar en consecuencia. Es una manera similar al tratamiento de la diabetes donde el nivel de 
glucosa en plasma se puede medir y se puede utilizar para regular las dosis de medicamentos; el enfoque del sistema 
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1. Introduction
In the last decade, advancements in information 
and communication technologies have given a 
boost to health monitoring systems. The introduc-
tion of electronic health records and digitalization 
of medical processes have enabled the develop-
ment of such monitoring systems and telemedicine 
applications. Nowadays, developed countries use 
these technologies to reduce the cost of national 
health systems (e.g. decreasing the length of stay 
in hospitals, re-occurrence and re-admission rates) 
(Polisena et al., 2009). Examples of complete health 
monitoring system are the Phillips Telehealth sys-
tem (philips, 2012), the Bosch Health Buddy solu-
tion (bosch, 2012) or the ibm Medical Home so-
lution (ibm, 2012). Several research projects have 
been developing monitoring systems for diseases 
such as diabetes (Jia et al., 2011), Congestive Heart 
Failure (Polisena et al., 2010) and Chronic Obtru-
sive Pulmonary Disease (Boulos et al., 2009).
Telehealth systems often take advantage of wear-
able technologies. These technologies include body 
area networks (ban) and body sensor and actuator 
networks (bs & an). They are employed to measure 
and monitor the current state of the user/patient. 
While bans can only be used for monitoring pur-
poses, bs & an can also be utilized to actuate. Thus 
actively manipulating the patients state or envi-
ronment. The same principle is used in systems for 
diabetes. Here, it is technically possible to measure 
the plasma glucose level in order to control the ba-
sal infusion rate of insulin that is being adminis-
trated subcutaneously by a pump (Hovorka, 2006). 
However, this principle cannot directly be applied 
to pd as no disease-specific biomarkers (Jankovic, 
2008) exist or are simply not practical (e.g. autop-
sy) (Samii et al., 2004). Currently, the best indica-
tor for drug needs in pd is the quality of motion. 
Thus, the difficulty to monitor patient’s symptoms 
and infer drug needs arises. However, to the best 
knowledge of the authors, this principle has not 
been successfully tested with pd.
The help system (Home-based Empowered Living 
for Parkinson’s disease patients) has been designed 
and implemented as a health monitoring system, 
which specifically targets the needs of people with 
Parkinson’s. pd is a progressive neurological condi-
tion which produces motor symptoms (e.g. rigidity, 
slowness of movement) and non-motor symptoms 
(e.g. cognition alterations, sleep disturbances). It 
is thought to affect more than five million people 
world-wide (Mathers et al., 2008). It is the fourth 
most frequent disorder of the nervous system, af-
ter epilepsy, brain vascular disease and Alzheimer. 
The average age at diagnosis is 60 years. Given the 
rapidly aging population, pd is becoming a major 
public health issue in Europe (Potocnik, 2008).
The help system proposes a solution to improve 
quality of life of pd patients based on the following 
three components.
•	 A bs & an consisting of several devices which 
monitor health parameters (e.g. blood pres-
sure) and body activity (e.g. motor symptoms) 
as well as administration of drugs.
•	 A remote point-of-care platform (PoC) that 
enabled clinical professionals to supervise pd 
patients.
•	 A telecommunication and services infrastruc-
ture for analyzing and transferring  informa-
tion from the user to the PoC and vice-versa.
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de ayuda tiene por objeto estimar los síntomas de la ep y ajustar la dosis de la medicación con el fin de reducir los 
síntomas. El sistema de vigilancia de la salud propuesto se compone de varios componentes: un sensor corporal y un 
actuador de red gestionado por un smartphone, una plataforma de monitorización remota para los médicos y clínicos 
profesionales, así como el uso de telecomunicaciones y servicios de infraestructura. La verdadera ventaja deriva de 
que tiene un constante control médico sin modificar drásticamente la vida cotidiana. El sistema help va a ser evalu-
ado en varias ciudades durante la primera parte del año 2012 en condiciones de vida diaria con pacientes con ep.
Palabras clave: enfermedad de parkinson, sensor corporal y actuador de red, sistema de vigilancia de la salud, vida 
asistida por el entorno
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The design deals not only with technological as-
pects, but it involves medical and social issues as 
well. help aims at filling the gap between these dif-
ferent knowledge domains by using a multidisci-
plinary, integrated approach derived from the col-
laboration of partners whose expertise stems from 
various fields.
The remainder of this paper is organized as fol-
lows: section 2 provides insights on clinical aspects 
of the pd disease; section 3 highlights relevant as-
pects related to the bs & an architecture and PoC. 
Finally, section 4 draws the conclusions.
2. Context
Parkinson’s Disease (pd) is a progressive, neurode-
generative disorder of the central nervous system 
which is characterized by the cardinal symptoms 
bradykinesia (slow movement), rigidity, resting 
tremor and postural instability. The cardinal fea-
tures mainly originate from a dopamine deficiency 
caused by a degeneration of dopamine producing 
neurons in part of the brain stem. Without treat-
ment, pd progresses over 5-10 years to a rigid, aki-
netic state in which patients are no longer capable 
of caring for themselves. 
Despite two centuries since James Parkinson first 
described the disease (in 1817), the cause of the 
disease remains unknown. Primarily, therapies aim 
at minimizing symptoms and maximizing (motor) 
function as well as quality of life. However, inten-
sive care is required, demanding the allocation of 
enormous resources besides the strictly medical 
ones. This leaves room for improvement of disease 
management and optimizing cost effectiveness of 
health care plans.
Both pharmacological and surgical treatments are 
available for pd. The primary treatment is based 
on medication, while surgical options (e.g. stimu-
lation, ablation) are not suitable for every patient. 
Thus they can only be applied in specific cases. 
Levodopa (L-dopa) is the most effective pharma-
cological agent for pd and remains the primary 
treatment for symptomatic patients. However, its 
long-term use is limited by motor complications 
and drug-induced dyskinesia (Nutt et al., 1984). 
Unfortunately, the majority of drugs for treating 
pd, particularly L-dopa, provide pulse stimulation 
of dopamine release rather than continuous stimu-
lation.
Once the patient has taken the medication, the 
symptoms relief and they regain control over their 
movements. Nonetheless due to remaining lack 
of dopamine production in the basal ganglia, the 
refilled dopamine does not last forever and motor 
symptoms are bound to reappear eventually unless 
another dose of medication is taken. Thus creating 
fluctuations between periods in which individuals 
show almost no motor symptoms (known as on 
period) and periods in which motor symptoms are 
present (known as off period). In an early stage of 
the disease, these fluctuations are predictable and 
cant be almost entirely avoided. However, as the 
disease progresses the desired effects of levodopa 
wear off. Thus the effectiveness of medication has 
a tendency to decrease and the symptoms reappear 
earlier than before.
With continued progression of the disease, fluctua-
tions between periods of mobility and immobility 
happen more frequently. In later stages of the dis-
ease, the fluctuations become less deterministic 
and totally unpredictable eventually (on-off phe-
nomenon) (Nutt et al., 1984).
The main issue is to maintain constant dopamine 
stimulation in order to reduce on-off fluctuations. 
Keeping a constant level of drugs avoids the dose-
dependent side effects and co-morbidity, while im-
proving the quality of life of patients. In an indirect 
way, fewer complications mean reducing possible 
hospitalizations, thus decreasing medical and as-
sistive costs. Furthermore, if less direct care is 
needed, their relatives and informal carers will also 
experience, in an indirect way, an increase of their 
quality of life, lowering the need to dedicate effort 
and time to take care of their elderly relatives.
In a more advanced phase of the disease, patients 
experience freezing episodes in which they actu-
ally freeze and are not able to perform any physical 
activity. Apart from motor symptoms patients can 
experience non-motor features including depres-
sion, sleep disturbances, dizziness, problems with 
speech, swallowing and sexual functioning. pd 
greatly impairs the patient’s quality of life, increas-
ing also caregiver distress.
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Making the patient’s medical data accessible on-
line to medical staff and putting them in contact by 
means of video conferences, enables a high degree 
of patient’s life comfort, giving them the tranquility 
to know that their doctor is always aware of their 
disease situation. When dealing with technological 
setups that support clinical trials and involve pa-
tients, three important aspects must be taken into 
account: user acceptance, usability and accessibil-
ity. All of them have been specifically addressed 
during the development of the help system.
Studies have indicated that drug delivery devices 
are generally well accepted by patients (La Van, 
2003; Curtis et al., 2007). Combing the devices 
with a transparent and automatic drug calcula-
tion ensures a high degree of usability. Medical 
information of the patient his gathered in an au-
tomatic way (e.g. motion detection) or with simple 
patient intervention (e.g. using a domestic blood 
pressure meter or answering questionnaires). Thus 
very little interaction is required by the patients. 
Furthermore, the interfaces are not dependent 
on the degree of disability of the person which 
makes the solution inherently accessible. In addi-
tion, the help system offers physicians and social 
care professionals tools to interact with their pa-
tients. Their medical and social situation can be 
handled online and remotely, which makes the 
help system especially accessible for patients with 
cognitive impairment.
3. Overview of help Monitoring System
The help health monitoring system is composed 
of several components which can be divided into 
the following categories: (1rst) a network of sen-
sors and actuators being worn by the patient, (2nd) 
a remote monitoring platform being used by doc-
tors and clinical professionals as well as (3rd) a 
telecommunication and services infrastructure. 
All of which are described in the following sub-
sections. The real advantage of the help system 
derives from having the constant medical control 
necessary for a pd patient without dramatically 
modifying his/her daily life.
Body Sensor and Actuator Network
The bs & an consists of two sensors, one actuator 
(either a subcutaneous pump or an intra-oral drug 
delivery device) and a smartphone. In general, 
both sensors provide information on the activity 
and drug needs of the patient. Based on this in-
formation the required amount of drug is deter-
mined and eventually administered to the patient 
by the actuator. The smartphone acts as a control 
station for the patient. It collects sensor informa-
tion and adjusts the actuators. All five components 
are highlighted and briefly described in Figure 1.
Figure 1: The subcutaneous pump is used for dy-
namic drug delivery. The pump has been modified 
to receive commands via a ZigBee interface
Figure 2: The intra-oral cartridge is used for con-
stant drug delivery. The base station has been 
equipped with a ZigBee communication module
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The actuator provides 
the means of deliver-
ing medication to the 
patient. A subcuta-
neous pump and an 
intra-oral drug deliv-
ery device cover both 
a dynamic (advanced 
stage of disease) and 
constant drug delivery 
(early and moderate 
stages of disease). The 
subcutaneous pump 
(see Figure 1) is worn 
by the patient and ca-
pable of dynamically 
deli vering medica-
tion. It can be remotely 
controlled in order to 
adjust the rate of in-
fusion. A constant de-
livery of medication is 
taken care of by the intra-oral device (see Figure 
2). While the intra-oral device and the base station 
are new developments, the subcutaneous pump is 
a modified version of a commercially available de-
vice which is extended by a wireless communica-
tion module based on the ZigBee communication 
standard.
A miniaturized cartridge is capable of delivering 
drugs according to the patient needs, in periods 
lasting days, weeks or months. An osmotic pump-
ing principle uses saliva to release highly precise 
a separately stored drug to the buccal mucosa 
(Herrlich et al., 2011), thus avoiding first pass me-
tabolism and drug plasma level fluctuations. The 
disposable cartridge is magnetically attached into 
a receptacle of a partial removable prosthesis and 
can be replaced by the patient himself.
The concept envisages varying the patient’s medi-
cation within boundaries specified by medical 
professionals. Relevant information like patient 
adherence to the therapy, medication and de-
livered amount of the cartridge can be deter-
mined by readout of its fill level, when placed on 
the base station.
The sensors provide measurements with which 
the patient’s state is estimated. A blood pressure 
monitor is used to supervise the overall health 
condition, whereas an inertial sensor provides rel-
evant information about the physical status (e.g. 
quantity of movement, motor symptoms and on/
off state). Information of the latter kind is used to 
infer drug needs. The inertial sensor is embedded 
into a device that offers enough computational ca-
pabilities to process data in real-time and has been 
designed to be used for long periods of time. The 
inertial body sensor is a single unit device which 
is encapsulated in a 78x37x10mm black case. It 
weights 125g (battery included). The sensor also 
has an embedded ZigBee module for wireless 
communication.
Internally, the device includes a micro-controller 
that handles the sub-systems (see Figure 3). The 
micro-controller provides the system with the ca-
pacity to acquire, order, compute and send data 
while handling other functions like energy man-
agement and user interface supervision.
The smartphone is a commercially available mobile 
device and holds a custom application as well as a 
special MicroSD card with an embedded ZigBee 
node. It is in charge of the management of the sen-
Figure 3: Movement Sensor Internal Scheme
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sors and actuators described above. It is also used 
to forward information gathered by the devices in 
the bs & an to the PoC. The smartphone has higher 
processing and memory capabilities with respect 
to sensor nodes and it can be used to 1) configure, 
monitor and control the sensor network, 2) collect 
and send data to a remote service center, and 3) lo-
cally process data (e.g. to manage alarms to be sent 
to the service center).
The smartphone is connected to the other devices 
by means of a ZigBee network and can be consid-
ered the sink (or the coordinator, following the 
ZigBee terminology) of a classical star topology 
network. In particular, the intra-oral device com-
municates to the smartphone when it is placed on 
the base station, as it would be unfeasible with the 
current technology to implant a similar radio in-
terface directly inside the cartridge.
The setup of the network must also ensure secu-
rity features, hence the communication between 
medical devices and smartphone is encrypted and 
point-to-point. In order to avoid that external de-
vices access sensitive data, the smartphone is in-
structed to establish a communication only with its 
own system devices. Moreover, each transmission 
contains the patient id, the device id and the time 
and date of transmission.
Point of Care Platform
The platform, that is being described in this sub-
section, is intended to be used by doctors and 
other clinical professionals. It shows information 
on the patient’s state (see Figure 4) and enables to 
review and adjust the treatment of each patient. 
A rule engine (re) system processes data coming 
from sensors and provides an estimation of the pa-
tient status. Furthermore, the drug needs are es-
timated. Both components are described in more 
details below. 
The re system suggests the amount of drug to be 
delivered to the patient. A clinician will review 
the drug dose suggestion and confirm or reject it. 
The drug dose calculation is estimated by using two 
input signals: information provided by the sensors 
and assignments provided by the physicians via 
PoC (a set of thresholds specific to each patient). 
Important figures are graphically represented (e.g. 
blood pressure, patient’s activity, number of steps, 
Figure 4: Illustrates the user interface provided to clinical professionals
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drug dose), so doctors can make wiser decisions 
(e.g. calling a relative if something looks strange 
or adjusting the drug dose). Furthermore, the PoC 
provides an interface for viewing alarms (e.g. pa-
tient has fallen, drug dose needs to be adjusted, 
etc.).
The re provides the service to diagnose a patient’s 
status based on a set of medical rules, which are 
supplied by clinical professionals and medical part-
ners. Each medical rule has a condition, a result 
or consequence and a frequency. Once a patient 
is found that matches a rule’s condition the result 
(e.g. raise an alarm) is applied. The conditions may 
have varying complexities which range from sim-
ple comparisons (e.g. equal, greater than, etc.) and 
mathematical operations (e.g. addition, division, 
etc.) to logic inference (e.g. conjunction, disjunc-
tion, etc.). The consequences are not limited to but 
usually raise an alarm which is then reviewed by 
medical professionals.
The frequency of a medical rule specifies how often 
it is checked. Rules with a high priority are checked 
up to every minute whereas rules with a lower pri-
ority might only be checked every 8 hours. The 
re periodically checks all rules according to their 
specified frequencies. The central database is que-
ried for new patient information and the rules are 
applied to it. The re can easily handle thresholds or 
settings specific to each patient.
Telecommunication and Services Infrastructure
The telecommunication infrastructure ties the pre-
viously mentioned components together. It pro-
vides the means to exchange data with the central 
server. Furthermore, the envisioned infrastructure 
also enables videoconferencing between a patient 
and relatives, social caretakers and doctors.
The smartphone transmits the latest patient data 
to the server and retrieves the inferred drug needs. 
The latest patient data is collected from the iner-
tial sensor and blood pressure monitor, whereas 
the drug needs are forwarded to the subcutaneous 
pump where the amount of delivered drug is ad-
justed.
The PoC retrieves the latest patient data from the 
server and displays them to medical personnel. 
Doctors have the opportunity to accept or reject 
changes in drug needs based on the provided data. 
Furthermore, the therapy for each patient can be 
adjusted.
4. Conclusions
The paper has provided insights on the help sys-
tem, detailing the system architecture and the bs 
& an created around a smartphone and medical 
devices. The whole system provides clinicians a 
telehealth tool for monitoring and treating pd in 
real-time. Help is envisioned to fulfill the so far 
unmet needs derived from the drawbacks of tra-
ditional pd treatments. Thus, it would improve the 
quality of life of pd patients and reduce co-morbid-
ity, and by doing so, enable the users to conduct an 
independent life at their homes.
The advantages of help will be validated during 
the last phase of the project. It will include trials 
with pd patients, which will provide the necessary 
feedback to assess the consistency and efficiency 
of the help solution and its compliance with such 
challenging objectives.
The development of the presented equipment im-
plies the confluence of very different competences, 
and may give the desired precise control while of-
fering the most efficient therapeutic outcomes. By 
validating the help system and demonstrating an 
increase in the quality of life of pd patients, this 
kind of innovative high-tech system may become a 
new commercial challenge for pharmaceutical and 
telehealth companies.
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